Advertisement

Topics

Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

2016-08-31 15:23:21 | BioPortfolio

Summary

In Non-alcoholic fatty (NAFLD) liver disease patients, the investigators hypothesized that rifaximin might act on Gram-negative bacteria and IBO thereby inhibiting LPS-mediated proinflammatory cytokine production. This work evaluates the efficacy of 6 months administration of rifaximin in NAFLD patients.

Description

The investigators aimed to study the effect of rifaximin on NAFLD. 126 patients with biopsy-proven NAFLD [42 steatosis, 84 non-alcoholic steatohepatitis (NASH)] were enrolled in this open-label, prospective, multicentric cohort study. BMI, AST, ALT, gamma glutamyl transferase (γ-GGT), lipid profile, homeostatic model assessment (HOMA), serum endotoxin, Toll-like receptor 4 (TlR4), interleukin-6 (IL-6), IL-10, tumor necrosis factor-α (TNF-α) and cytokeratin-18 (CK-18) levels were measured before and after a 6 month administration of rifaximin (1100-1200 mg/day).

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Non-alcoholic Fatty Liver Disease

Intervention

Rifaximin

Location

Nasser H Mousa,MD,mousa_medic@yahoo.com. +201227029213
Mansoura
Egypt

Status

Completed

Source

Mansoura University

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-08-31T15:23:21-0400

Clinical Trials [1882 Associated Clinical Trials listed on BioPortfolio]

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive...

The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease

The principal purpose of this study is to determine whether increased intakes of n-3 polyunsaturated (omega-3) fatty acids will reduce the amount of fat stored in the liver in patients wit...

Genetic Studies of Non-Alcoholic Fatty Liver Disease

Background: - Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions. Researchers want to study fatty liver disease b...

Effect of Ginger Supplement on Non-alcoholic Fatty Liver

The hypothesis of this study was that ginger supplement consumption can be introduced as a new therapeutic strategy for non-alcoholic fatty liver disease through the improved body antioxid...

A Study of RO5093151 in Patients With Non-Alcoholic Fatty Liver Disease

This multi-center, double-blind, randomized, placebo-controlled study will evaluate the change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with non-alcoholic...

PubMed Articles [19484 Associated PubMed Articles listed on BioPortfolio]

Future therapy for non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease is a leading cause of chronic liver disease and can lead to cirrhosis, hepatocellular cancer and end stage liver disease. It is also associated with increased cardiov...

Impact of body mass index in liver transplantation for nonalcoholic fatty liver disease and alcoholic liver disease.

This study evaluates long-term outcomes and body mass index (BMI) following liver transplantation (LT) for non-alcoholic fatty liver disease (NAFLD) in comparison with alcoholic liver disease (ALD).

Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk.

With the advent and subsequent success of antiretroviral therapy, HIV infection has largely become a chronic condition and is increasingly seen alongside metabolic disorders such as dyslipidemia and i...

Serum magnesium concentration is independently associated with non-alcoholic fatty liver and non-alcoholic steatohepatitis.

The pathogenesis of non-alcoholic fatty liver disease (NAFLD) has not been well recognized yet.

Response to "Sleep habits and non-alcoholic fatty liver disease: risk assessment by adjusting confounders".

We thank Tomoyuki Kawada for the comments(1) in response to our recent article in Journal of Diabetes titled 'Short sleep duration and longer daytime napping are associated with non-alcoholic fatty li...

Medical and Biotech [MESH] Definitions

Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.

Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.

Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Cytoplasmic hyaline inclusions in HEPATOCYTES. They are associated with ALCOHOLIC STEATOHEPATITIS and non-alcoholic STEATOHEPATITIS, but are also present in benign and malignant hepatocellular neoplasms, and metabolic, toxic, and chronic cholestatic LIVER DISEASES.

More From BioPortfolio on "Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...


Searches Linking to this Trial